Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Rajeev K. Shrimali"'
Autor:
Samir N. Khleif, Seema Gupta, Mikayel Mkrtichyan, John E. Janik, Scott A. Hammond, Harlan Robins, Catherine Sanders, Erik Yusko, Rachel M. Gittelman, Pankaj Gaur, Sudha Ananth, Peng Zeng, Vivek Verma, Shamim Ahmad, Rajeev K. Shrimali
Effects of the combination therapy of anti-OX40 and anti-PD-1 Abs with tumor vaccine on spleen and tumor T-cell infiltration and clonality.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44c63ff14df19403c3f2a7fca5a301e1
https://doi.org/10.1158/2326-6066.22539581
https://doi.org/10.1158/2326-6066.22539581
Autor:
Samir N. Khleif, Seema Gupta, Mikayel Mkrtichyan, John E. Janik, Scott A. Hammond, Harlan Robins, Catherine Sanders, Erik Yusko, Rachel M. Gittelman, Pankaj Gaur, Sudha Ananth, Peng Zeng, Vivek Verma, Shamim Ahmad, Rajeev K. Shrimali
Combination therapies that depend on checkpoint inhibitor antibodies (Abs) such as for PD-1 or its ligand (PD-L1) together with immune stimulatory agonist Abs like anti-OX40 are being tested in the clinic to achieve improved antitumor effects. Here,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5c0801e54b2055f9ba4cd12f3c386703
https://doi.org/10.1158/2326-6066.c.6549134.v1
https://doi.org/10.1158/2326-6066.c.6549134.v1
Autor:
Samir N. Khleif, Seema Gupta, Mikayel Mkrtichyan, John E. Janik, Scott A. Hammond, Harlan Robins, Catherine Sanders, Erik Yusko, Rachel M. Gittelman, Pankaj Gaur, Sudha Ananth, Peng Zeng, Vivek Verma, Shamim Ahmad, Rajeev K. Shrimali
Evaluation of expression of OX40, PD-1, and PD-L1 and proliferation and apoptosis in CD8+ T-cells in vitro.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4c4154d895a255c0807381cb59d5a80
https://doi.org/10.1158/2326-6066.22539584.v1
https://doi.org/10.1158/2326-6066.22539584.v1
Autor:
Samir N. Khleif, Seema Gupta, Mikayel Mkrtichyan, John E. Janik, Scott A. Hammond, Harlan Robins, Catherine Sanders, Erik Yusko, Rachel M. Gittelman, Pankaj Gaur, Sudha Ananth, Peng Zeng, Vivek Verma, Shamim Ahmad, Rajeev K. Shrimali
Supplementary Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::615d975cb0e07c871f0a46f68a354f77
https://doi.org/10.1158/2326-6066.22539587
https://doi.org/10.1158/2326-6066.22539587
Autor:
Mikayel Mkrtichyan, Pankaj Gaur, John Edward Janik, Stacey L. Bjorgaard, Samir N. Khleif, Genevieve M. Boland, Moshe Sade-Feldman, Seema Gupta, Ming Tan, Phillip Wong, Rahul Nandre, Rajeev K Shrimali, Scott A. Hammond, Shamim Ahmad, Gad Getz, José A. López, Jedd D. Wolchok, Nir Hacohen, Hua Wang, Taha Merghoub, Vivek Verma, Keren Yizhak, Jennifer A. Wargo, Sumin Lu, Winjie Dai, Keith T. Flaherty, Jingjing Qi, Ryan J. Sullivan
Publikováno v:
Nature Immunology. 20:1231-1243
Understanding resistance to antibody to programmed cell death protein 1 (PD-1; anti-PD-1) is crucial for the development of reversal strategies. In anti-PD-1-resistant models, simultaneous anti-PD-1 and vaccine therapy reversed resistance, while PD-1
Autor:
Sudha Ananth, Shamim Ahmad, Takumi Kumai, Samir N. Khleif, Esteban Celis, Rasha Abu Eid, Zuzana Berrong, Paulo C. Rodriguez, Rajeev K. Shrimali, Yuan Lin, John Edward Janik, Mason Webb, Mikayel Mkrtichyan
Publikováno v:
Cancer Research. 77:4135-4145
Inhibition of specific Akt isoforms in CD8+ T cells promotes favored differentiation into memory versus effector cells, the former of which are superior in mediating antitumor immunity. In this study, we investigated the role of upstream PI3K isoform
Autor:
Rajeev K. Shrimali, Ghazaleh Shoja E Razavi, Zuzana Berrong, Seema Gupta, Shamim Ahmad, Robert Petit, Adelaida Matevosyan, Mikayel Mkrtichyan, Samir N. Khleif, Grigori Okoev
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-9 (2017)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background We previously demonstrated that in addition to generating an antigen-specific immune response, Listeria monocytogenes (Lm)-based immunotherapy significantly reduces the ratio of regulatory T cells (Tregs)/CD4+ and myeloid-derived suppresso
Autor:
Raed Samara, Rajeev K. Shrimali, Atbin Doroodchi, Shamim Ahmad, Samir N. Khleif, Paulo C. Rodriguez, Rasha Abu-Eid, Vivek Verma, Zuzana Berrong, Mason Webb, Mikayel Mkrtichyan
Publikováno v:
Cancer Research. 77:1892-1904
To modulate T-cell function for cancer therapy, one challenge is to selectively attenuate regulatory but not conventional CD4+ T-cell subsets [regulatory T cell (Treg) and conventional T cell (Tconv)]. In this study, we show how a functional dichotom
Autor:
Vivek, Verma, Rajeev K, Shrimali, Shamim, Ahmad, Winjie, Dai, Hua, Wang, Sumin, Lu, Rahul, Nandre, Pankaj, Gaur, Jose, Lopez, Moshe, Sade-Feldman, Keren, Yizhak, Stacey L, Bjorgaard, Keith T, Flaherty, Jennifer A, Wargo, Genevieve M, Boland, Ryan J, Sullivan, Gad, Getz, Scott A, Hammond, Ming, Tan, Jingjing, Qi, Phillip, Wong, Taha, Merghoub, Jedd, Wolchok, Nir, Hacohen, John E, Janik, Mikayel, Mkrtichyan, Seema, Gupta, Samir N, Khleif
Publikováno v:
Nature immunology. 20(9)
Understanding resistance to antibody to programmed cell death protein 1 (PD-1; anti-PD-1) is crucial for the development of reversal strategies. In anti-PD-1-resistant models, simultaneous anti-PD-1 and vaccine therapy reversed resistance, while PD-1
Autor:
Nagaraj Gowda, Sureshkumar Vadlamani, Amit A. Dhudashiya, Rajeev K. Shrimali, Rashmi Nair, Leena Khare Satyam, Murali Ramachandra, Sreenivas Adurthi, Krishnaprasad Subbarao, Sriharibabu Vunnum, Raghuveer Ramachandra, Koteswararao Vemula, Dodderi S. Samiulla, Pottayil G. Sasikumar
Publikováno v:
Molecular cancer therapeutics. 18(6)
Pioneering success of antibodies targeting immune checkpoints such as PD-1 and CTLA4 has opened novel avenues for cancer immunotherapy. Along with impressive clinical activity, severe immune-related adverse events (irAE) due to the breaking of immune